Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

Table 5 Bacterial pathogens isolated on days 0 and 7 from lower respiratory tract lesions, bronchoalveolar lavage and nasal swabs, minimum inhibitory concentrations (MIC) and susceptibilities to marbofloxacin and enrofloxacin

MIC₅₀, MIC₉₀, lowest concentrations (μg/mL) of the antimicrobial for which 50 and 90% of the isolates were inhibited, respectively; n, total number of isolates from lung/lower respiratory tract, bronchoalveolar lavage and nasal swabs, combined, for which MIC was determined; n/a susceptibility data not available; nc, not calculated for <10 isolates; S, percentage of isolates within a species that were susceptible to the antimicrobial based on European susceptibility monitoring and where available CLSI breakpoints [28, 29, 38]

ISSN: 2055-5660